Evidence map›Paper›PMID 34337539›Full record

ArticleEuropean urology open science2021

Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease.

Simon R Walker, Ramy Abdelsalam, Sunita Ghosh, Julie Livingstone, Nallasivam Palanisamy, Paul C Boutros, Steven M Yip, Susan P Lees-Miller, Tarek A Bismar

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Simon R WalkerDepartment of Pathology and Laboratory Medicine, University of Calgary Cumming School of Medicine and Alberta Precision Laboratories, Calgary, AB, Canada.
Ramy AbdelsalamDepartment of Pathology and Laboratory Medicine, University of Calgary Cumming School of Medicine and Alberta Precision Laboratories, Calgary, AB, Canada.
Sunita GhoshDepartment of Medical Oncology, Faculty of Medicine and Dentistry, University of Alberta, and Alberta Health Services-Cancer Control, Edmonton, AB, Canada.
Julie LivingstoneDepartments of Human Genetics and Urology, University of California, Los Angeles, CA, USA.
Nallasivam PalanisamyDepartment of Urology, Vattikuti Urology Institute, Henry Ford Health System Detroit, MI, USA.
Paul C BoutrosDepartments of Human Genetics and Urology, University of California, Los Angeles, CA, USA.
Steven M YipTom Baker Cancer Centre, Calgary, AB, Canada.
Susan P Lees-MillerDepartments of Oncology, Biochemistry and Molecular Biology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Tarek A BismarDepartment of Pathology and Laboratory Medicine, University of Calgary Cumming School of Medicine and Alberta Precision Laboratories, Calgary, AB, Canada.
University of Calgary · CAUniversity of California, Los Angeles · USAlberta Health Services · CAHenry Ford Health System · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundAtaxia Telangiectasia Mutated (ATM) serine/threonine protein kinase is a known tumor suppressor, involved in DNA damage repair. It has prognostic and predictive therapeutic implications and is associated with aggressive prostate cancer (PCa).

objectiveTo investigate the prognostic value of ATM protein expression in PCa patients and assessed the combined value of ATM, ERG, and PTEN status. DESIGN SETTING AND

participantsThis study consisted of 303 patients with incidental, locally advanced, and castrate-resistant PCa by transurethral resection of the prostate (TURP). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: TURP samples from 303 PCa patients were assessed by immunohistochemistry (IHC for ATM, ERG, and PTEN. Individual and combined marker status were correlated with International Society of Urological Pathology Gleason grade group, overall survival (OS), and PCa-specific mortality (PCSM). RESULTS AND LIMITATIONS: Decreased ATM expression (negative/weak intensity) occurred in 164/303 (54.1%) patients, and was associated with shorter OS and higher PCSM (

conclusionsDecreased ATM protein expression is associated with poor outcomes in advanced PCa patients. Patients with combined low ATM/PTEN negative expression are at the highest risk for reduced OS and PCSM. Assessing the combined status of ATM/PTEN by IHC in PCa patients may aid in risk stratification relative to OS and PCSM. Moreover, since ATM plays an integral role in DNA damage response pathways, future studies will enhance our understanding of how outcomes of patients with altered ATM and PTEN expression can be improved further with poly-ADP ribose polymerase inhibitors (PARPi), combinations of PARPi and androgen receptor-targeted therapies, as well as platinum-based chemotherapies. PATIENT SUMMARY: Lower ATM intensity is associated with increased cancer-specific mortality in prostate cancer patients. Patients with lower ATM and PTEN negative expression showed decreased overall survival and increased cancer mortality compared with controls.

Indexed as

Androgen deprivation therapyATMCancer-specific mortalityERGGleason scoreImmunohistochemistryOverall survivalPoly-ADP ribose polymerase and ATR inhibitorsProtein expressionPTEN

Identifiers

PMID34337539
PMCPMC8317877
OpenAlexW3169833232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.